New Triple-Threat treatment trial targets tough head & neck cancer
NCT ID NCT05807880
Summary
This study is testing a new three-drug combination as the first treatment for people whose nasopharyngeal cancer (a type of head and neck cancer) has returned or spread to other parts of the body. The treatment involves taking two medications (anlotinib and capecitabine) and receiving an immunotherapy drug (penpulimab). The main goal is to see how long patients live without their cancer getting worse, while also monitoring side effects and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.